‘A Real Regulatory Dilemma Here’: What We Heard This Week

by iMARS Staff 24. November 2024 Health 0

(MedPage Today) — “It’s a real regulatory dilemma here.” — Donald Kohn, MD, of the University of California Los Angeles, at an FDA advisory committee meeting to discuss whether the bleeding reversal agent andexanet alfa (Andexxa) should get…